Advanced search
1 file | 217.76 KB

Cancer risk in immune-mediated inflammatory diseases (IMID)

Author
Organization
Abstract
Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors. This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors. Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce. This review provides clinicians with a solid background to help them in making decisions about treatment of immune-mediated diseases in patients with a tumor history. This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86.
Keywords
Antirheumatic agents, Autoimmune diseases, Biological products, Cancer, Inflammation, Tumor necrosis factor, TUMOR-NECROSIS-FACTOR, SYSTEMIC-LUPUS-ERYTHEMATOSUS, RANDOMIZED CONTROLLED-TRIALS, POPULATION-BASED COHORT, LONG-TERM SAFETY, NF-KAPPA-B, NONMELANOMA SKIN-CANCER, RHEUMATOID-ARTHRITIS, BOWEL-DISEASE, ULCERATIVE-COLITIS

Downloads

  • 2237 13Beyaert.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 217.76 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Beyaert, Rudi, Laurent Beaugerie, Gert Van Assche, Lieve Brochez, Jean-Christophe Renauld, Manuelle Viguier, Veronique Cocquyt, et al. 2013. “Cancer Risk in Immune-mediated Inflammatory Diseases (IMID).” Molecular Cancer 12.
APA
Beyaert, R., Beaugerie, L., Van Assche, G., Brochez, L., Renauld, J.-C., Viguier, M., Cocquyt, V., et al. (2013). Cancer risk in immune-mediated inflammatory diseases (IMID). MOLECULAR CANCER, 12.
Vancouver
1.
Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld J-C, Viguier M, et al. Cancer risk in immune-mediated inflammatory diseases (IMID). MOLECULAR CANCER. 2013;12.
MLA
Beyaert, Rudi, Laurent Beaugerie, Gert Van Assche, et al. “Cancer Risk in Immune-mediated Inflammatory Diseases (IMID).” MOLECULAR CANCER 12 (2013): n. pag. Print.
@article{4144036,
  abstract     = {Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors.
This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.
Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.
This review provides clinicians with a solid background to help them in making decisions about treatment of immune-mediated diseases in patients with a tumor history.
This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86.},
  articleno    = {98},
  author       = {Beyaert, Rudi and Beaugerie, Laurent and Van Assche, Gert and Brochez, Lieve and Renauld, Jean-Christophe and Viguier, Manuelle and Cocquyt, Veronique and Jerusalem, Guy and Machiels, Jean-Pascal and Prenen, Hans and Masson, Pierre and Louis, Edouard and De Keyser, Filip},
  issn         = {1476-4598},
  journal      = {MOLECULAR CANCER},
  keywords     = {Antirheumatic agents,Autoimmune diseases,Biological products,Cancer,Inflammation,Tumor necrosis factor,TUMOR-NECROSIS-FACTOR,SYSTEMIC-LUPUS-ERYTHEMATOSUS,RANDOMIZED CONTROLLED-TRIALS,POPULATION-BASED COHORT,LONG-TERM SAFETY,NF-KAPPA-B,NONMELANOMA SKIN-CANCER,RHEUMATOID-ARTHRITIS,BOWEL-DISEASE,ULCERATIVE-COLITIS},
  language     = {eng},
  pages        = {12},
  title        = {Cancer risk in immune-mediated inflammatory diseases (IMID)},
  url          = {http://dx.doi.org/10.1186/1476-4598-12-98},
  volume       = {12},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: